The financial springboard supplied by the successful JAK inhibitor Jakafi is allowing Incyte Corp. to tackle many new mechanisms all at once, including a second-generation PI3 kinase inhibitor and some of the hottest targets in immuno-oncology today – OX40 and GITR agonists – and rebound from some R&D disappointments.
The company showcased its full pipeline at the American Association for Cancer Research annual meeting in April and is planning...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?